Previous 10 | Next 10 |
2023-03-27 15:13:57 ET Summary Vor Biopharma Inc. is the brainchild of Dr. Siddhartha Mukherjee. Its core idea is to make CAR-Ts safer by using stem cells. I must admit the idea is interesting, and I would like to see more data from this company. If you are buying Vo...
2023-03-24 14:10:31 ET Cell therapy developer Vor Biopharma ( NASDAQ: VOR ) added ~15% marking the highest intraday rise in more than three months, after announcing Q4 2022 results on Friday with an update on its liquidity position. The Cambridge, Massachusetts-bas...
2023-03-24 12:20:59 ET Gainers: Silvergate Capital Corporation ( SI ) +66% . NaaS Technology ( NAAS ) +36% . Assure Holdings ( IONM ) +21% . Dermata Therapeutics ( DRMA ) +21% . ReNew Energy Global ( RNW ) +20% . GH Research ...
2023-03-23 16:42:34 ET Vor Biopharma press release ( NASDAQ: VOR ): Q4 Non-GAAP EPS of -$0.53 beats by $0.04 . Cash, cash equivalents and investments were $230.2 million as of December 31, 2022, which is projected to fund operations into the first quarter of 2025. ...
Initial clinical data supports founding vision that engineered hematopoietic stem cells can enable treatment options after AML transplant Additional trem-cel data expected by year-end 2023; VCAR33 ALLO on track for IND submission in first half of 2023 $116M financing...
Trem-cel exhibited robust engraftment five months post-transplant through three cycles of Mylotarg Mylotarg treatment enriched CD33-negative donor hematopoiesis Second patient successfully received trem-cel transplant and achieved neutrophil engraftment and platelet recovery ...
CAMBRIDGE, Mass., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that clinical data from the first patient treated in VBP101, its Phase 1/2a multicenter, open-label, first-in-human study of trem-cel (formerly VOR33) i...
CAMBRIDGE, Mass., Jan. 12, 2023 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate virtually in B. Riley Securities’ 3rd Annual Oncology Conference. B. Riley Securities’ 3rd Annual O...
Cell and genome engineering company Vor Bio ( NASDAQ: VOR ) has priced ~$115.8M underwritten offering and private placement. The company has agreed to sell 15.30M shares at $4.30 per share as part of the offering. Before deducting the underwriting discounts and commissions and off...
CAMBRIDGE, Mass., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the pricing of an underwritten offering and a private placement, with combined gross proceeds of approximately $115.8 million. In the underwritten...
News, Short Squeeze, Breakout and More Instantly...
On-track for trem-cel and VCAR33 ALLO clinical updates in the second half of 2024 Trem-cel trial expanded to include patients with myelodysplastic syndromes (MDS); Mylotarg™ dosing has advanced to the third cohort CAMBRIDGE, Mass., May 09, 2024 (GLOBE NEWSWI...
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Fouad Namouni, M.D., to its Board of Directors. Dr. Namouni currently serves as President of Research & Development at Blueprint M...
Trem-cel and VCAR33 ALLO clinical trial data expected in the second half of 2024 VCAR33 ALLO granted Fast Track and Orphan Drug Designation by U.S. Food & Drug Administration Cash runway extends into second half of 2025 CAMBRIDGE, Mass., March...